Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRIT EXTENSION: Relugolix Combination Therapy for Endometriosis Pain
NCT03654274Phase 3Completed
- Sponsor
- Myovant Sciences
- Start
- May 2018
- Primary completion
- Dec 2021
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 20
01
Overview
Phase 3, open-label, single-arm trial of relugolix in endometriosis, sponsored by Myovant Sciences. Primary endpoints: Percentage Of Participants Who Meet The Dysmenorrhea Responder Criteria at 104 weeks and Percentage Of Participants Who Meet The NMPP Responder Criteria at 104 weeks. Started May 2018; status: completed.
02
Drugs
relugolix
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT03654274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03654274.